1700 related articles for article (PubMed ID: 20385246)
21. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET.
Verhoeff NP; Wilson AA; Takeshita S; Trop L; Hussey D; Singh K; Kung HF; Kung MP; Houle S
Am J Geriatr Psychiatry; 2004; 12(6):584-95. PubMed ID: 15545326
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic Accuracy of Amyloid versus
Lesman-Segev OH; La Joie R; Iaccarino L; Lobach I; Rosen HJ; Seo SW; Janabi M; Baker SL; Edwards L; Pham J; Olichney J; Boxer A; Huang E; Gorno-Tempini M; DeCarli C; Hepker M; Hwang JL; Miller BL; Spina S; Grinberg LT; Seeley WW; Jagust WJ; Rabinovici GD
Ann Neurol; 2021 Feb; 89(2):389-401. PubMed ID: 33219525
[TBL] [Abstract][Full Text] [Related]
23. In vivo evaluation of amyloid deposition and brain glucose metabolism of 5XFAD mice using positron emission tomography.
Rojas S; Herance JR; Gispert JD; Abad S; Torrent E; Jiménez X; Pareto D; Perpiña U; Sarroca S; Rodríguez E; Ortega-Aznar A; Sanfeliu C
Neurobiol Aging; 2013 Jul; 34(7):1790-8. PubMed ID: 23402900
[TBL] [Abstract][Full Text] [Related]
24. Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients.
Lehmann M; Ghosh PM; Madison C; Karydas A; Coppola G; O'Neil JP; Huang Y; Miller BL; Jagust WJ; Rabinovici GD
J Neurol Neurosurg Psychiatry; 2014 Mar; 85(3):266-73. PubMed ID: 23965289
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.
Ossenkoppele R; Tolboom N; Foster-Dingley JC; Adriaanse SF; Boellaard R; Yaqub M; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):990-1000. PubMed ID: 22441582
[TBL] [Abstract][Full Text] [Related]
26. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
[TBL] [Abstract][Full Text] [Related]
27. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
[TBL] [Abstract][Full Text] [Related]
28. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
[TBL] [Abstract][Full Text] [Related]
29. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies.
Thompson PW; Ye L; Morgenstern JL; Sue L; Beach TG; Judd DJ; Shipley NJ; Libri V; Lockhart A
J Neurochem; 2009 Apr; 109(2):623-30. PubMed ID: 19226369
[TBL] [Abstract][Full Text] [Related]
30. Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.
Oh H; Madison C; Baker S; Rabinovici G; Jagust W
Brain; 2016 Aug; 139(Pt 8):2275-89. PubMed ID: 27190008
[TBL] [Abstract][Full Text] [Related]
31. Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease.
Braskie MN; Klunder AD; Hayashi KM; Protas H; Kepe V; Miller KJ; Huang SC; Barrio JR; Ercoli LM; Siddarth P; Satyamurthy N; Liu J; Toga AW; Bookheimer SY; Small GW; Thompson PM
Neurobiol Aging; 2010 Oct; 31(10):1669-78. PubMed ID: 19004525
[TBL] [Abstract][Full Text] [Related]
32. 2-(1-{6-[(2-[fluorine-18]fluoroethyl)(methyl) amino]-2-naphthyl} ethylidene)malononitrile (FDDNP) positron emission tomography patterns in nondemented populations.
Shin J; Lee SY
Am J Geriatr Psychiatry; 2010 Feb; 18(2):187; author reply 188. PubMed ID: 20104075
[No Abstract] [Full Text] [Related]
33. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
[TBL] [Abstract][Full Text] [Related]
34. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding.
Tolboom N; van der Flier WM; Yaqub M; Boellaard R; Verwey NA; Blankenstein MA; Windhorst AD; Scheltens P; Lammertsma AA; van Berckel BN
J Nucl Med; 2009 Sep; 50(9):1464-70. PubMed ID: 19690025
[TBL] [Abstract][Full Text] [Related]
35. Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia.
Small GW; Siddarth P; Burggren AC; Kepe V; Ercoli LM; Miller KJ; Lavretsky H; Thompson PM; Cole GM; Huang SC; Phelps ME; Bookheimer SY; Barrio JR
Arch Gen Psychiatry; 2009 Jan; 66(1):81-7. PubMed ID: 19124691
[TBL] [Abstract][Full Text] [Related]
36. Prefrontal hypometabolism in Alzheimer disease is related to longitudinal amyloid accumulation in remote brain regions.
Klupp E; Grimmer T; Tahmasian M; Sorg C; Yakushev I; Yousefi BH; Drzezga A; Förster S
J Nucl Med; 2015 Mar; 56(3):399-404. PubMed ID: 25678488
[TBL] [Abstract][Full Text] [Related]
37. Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease.
Bunai T; Kakimoto A; Yoshikawa E; Terada T; Ouchi Y
J Alzheimers Dis; 2019; 69(2):529-538. PubMed ID: 31104023
[TBL] [Abstract][Full Text] [Related]
38. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.
Chiotis K; Saint-Aubert L; Savitcheva I; Jelic V; Andersen P; Jonasson M; Eriksson J; Lubberink M; Almkvist O; Wall A; Antoni G; Nordberg A
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1686-99. PubMed ID: 26996778
[TBL] [Abstract][Full Text] [Related]
39. Brain [18F]FDDNP binding and glucose metabolism in advanced elderly healthy subjects and Alzheimer's disease patients.
Tauber C; Beaufils E; Hommet C; Ribeiro MJ; Vercouillie J; Vierron E; Mondon K; Cottier JP; Gissot V; Guilloteau D; Camus V
J Alzheimers Dis; 2013; 36(2):311-20. PubMed ID: 23609763
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Lavado-Pérez C; Bravo-Ferrer Z; Rodríguez-Rodríguez E; Sánchez-Juan P; Carril JM
Nucl Med Commun; 2016 Nov; 37(11):1189-96. PubMed ID: 27341411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
